Share-based Payment Arrangement, Expense of 4D Molecular Therapeutics, Inc. from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
4D Molecular Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • 4D Molecular Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,519,000, a 30% decline year-over-year.
  • 4D Molecular Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $24,042,000, a 1.7% decline year-over-year.
  • 4D Molecular Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $26,116,000, a 33% increase from 2023.
  • 4D Molecular Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $19,665,000, a 15% increase from 2022.
  • 4D Molecular Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $17,121,000, a 24% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

4D Molecular Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $24,042,000 $4,519,000 -$1,971,000 -30% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $26,013,000 $4,958,000 -$1,115,000 -18% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $27,128,000 $6,986,000 +$1,012,000 +17% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $26,116,000 $7,579,000 +$1,666,000 +28% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
Q3 2024 $24,450,000 $6,490,000 +$1,928,000 +42% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $22,522,000 $6,073,000 +$1,104,000 +22% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $21,418,000 $5,974,000 +$1,753,000 +42% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $19,665,000 $5,913,000 +$1,567,000 +36% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $18,098,000 $4,562,000 +$42,000 +0.93% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $18,056,000 $4,969,000 +$647,000 +15% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $17,409,000 $4,221,000 +$288,000 +7.3% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $17,121,000 $4,346,000 +$615,000 +16% 01 Oct 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $16,506,000 $4,520,000 +$597,000 +15% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $15,909,000 $4,322,000 +$506,000 +13% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $15,403,000 $3,933,000 +$1,604,000 +69% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $13,799,000 $3,731,000 +$2,014,000 +117% 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
Q3 2021 $11,785,000 $3,923,000 +$2,776,000 +242% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $9,009,000 $3,816,000 +$2,779,000 +268% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $6,230,000 $2,329,000 +$1,246,000 +115% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $4,984,000 $1,717,000 01 Oct 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
Q3 2020 $1,147,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $1,037,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $1,083,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1

4D Molecular Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $26,116,000 +$6,451,000 +33% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
2023 $19,665,000 +$2,544,000 +15% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
2022 $17,121,000 +$3,322,000 +24% 01 Jan 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
2021 $13,799,000 +$8,815,000 +177% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
2020 $4,984,000 +$1,443,000 +41% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
2019 $3,541,000 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.